GLP-1 trade? McKesson is your stock, this investor says

April 28, 2026 at 3:05pm ADT 1 min read
Last updated on April 28, 2026 at 3:05pm ADT
McKesson stock

Goodreid Investment Counsel president and CEO Gordon Reid told BNN Bloomberg’s Market Call on April 23 that McKesson (McKesson Stock Quote, Chart, News, Analysts, Financials NYSE:MCK) remains an attractive, stable healthcare name with long-term growth tied to pharmaceutical distribution demand.

Reid noted that McKesson is the world’s largest pharmaceutical distributor, handling more than one billion prescriptions a year, and should benefit from aging demographics and rising drug volumes.

“It’s incredibly stable,” Reid said. “And GLP-1 drugs are a huge growth area for McKesson.”

He said the company also offers consistency, quality and a reasonable valuation.

“It’s predictable. We love that,” Reid said. “Trading at an undemanding multiple and a good quality company.”

McKesson shares have gained 19.31% over the past 12 months and 342.2% over five years. Of the analysts covering the stock, 16 rate it “Buy,” two “Hold” and none “Sell,” with a consensus price target of US$1,002.94.

-30-

✖

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Author photo

Rod Weatherbie

Writer

Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.